Vertex Pharmaceuticals Incorporated
VRTX
$388.52
-$6.60-1.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.03B | 646.30M | 913.00M | 1.05B | -3.59B |
| Total Depreciation and Amortization | 51.70M | 48.40M | 21.30M | 53.20M | 54.00M |
| Total Amortization of Deferred Charges | -- | -- | 25.20M | -- | -- |
| Total Other Non-Cash Items | 120.90M | 392.70M | 185.30M | 113.70M | 27.40M |
| Change in Net Operating Assets | -132.40M | -268.50M | -560.20M | 157.50M | -241.40M |
| Cash from Operations | 1.07B | 818.90M | 584.60M | 1.37B | -3.75B |
| Capital Expenditure | -145.70M | -40.70M | -92.60M | -67.70M | -69.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -338.80M | -15.10M | -729.30M | -280.30M | -394.70M |
| Cash from Investing | -484.50M | -55.80M | -821.90M | -348.00M | -463.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.30M | -1.30M | -1.30M | -5.40M | -13.70M |
| Issuance of Common Stock | 49.10M | 16.70M | 34.30M | 8.40M | 55.00M |
| Repurchase of Common Stock | -397.70M | -696.60M | -425.20M | -391.40M | -400.80M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 700.00K | 800.00K | 900.00K | 900.00K | 900.00K |
| Cash from Financing | -349.20M | -680.40M | -391.30M | -387.50M | -358.60M |
| Foreign Exchange rate Adjustments | 57.20M | 30.50M | -47.30M | 22.80M | -2.50M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 296.60M | 113.20M | -675.90M | 657.10M | -4.58B |